|
Bayer beendet Kollaboration (Entwicklung CAR-T Zelltherapien)
investors.atarabio.com/news-events/...des-update-on-strategic
Atara stürzt nach einer nicht schlüssigen Phase-2-MS-Analyse
www.fiercebiotech.com/biotech/...stifying-phase-2-data-review
Hoher Cashburn
Zahlen für Q3/22
- will be sufficient to fund the Company’s planned operations into Q1 2024
investors.atarabio.com/news-events/...nces-third-quarter-2022
Zahlen für Q4/22
- Ebvallo EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023
- Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®
- ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023
- Cash Runway Extended into Q2 2024
investors.atarabio.com/news-events/...fourth-quarter-and-full
Zahlen für Q1/23
- fund the Company’s planned operations into Q2 2024
investors.atarabio.com/news-events/...nces-first-quarter-2023
Der Cashburn sieht übel aus.
Zahlen für Q3/23
- Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets
- Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs
- Cash Runway into Q3 2025
- ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November
investors.atarabio.com/news-events/...expanded-global-tab-cel
investors.atarabio.com/news-events/...mary-analysis-data-from
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
88 | Langfristinvest mit Prime Status | Evidencebased | Highländer49 | 07.02.24 10:37 |